[ad_1]
In February, the Government procured some 100 million doses of the vaccine with another 90 million to follow.
The deal was estimated to be worth up to £1.19billion (€1.4billion).
According to Valneva, the vaccine has produced a “neutralising antibody seroconversion rate above 95 percent”.
Even more impressively, the Phase Three trials have not recorded any severe cases of COVID-19.
The company is now preparing to trail the vaccine on children aged five to 12, to gauge its use as a booster shot.
This is a breaking story. Refresh the page to see more.
[ad_2]
